Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

BACKGROUND: The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients with cancer is unknown. We aimed to assess the safety and immunogenicity of the BNT162b2 (Pfizer–BioNTech) vaccine in patients with cancer. METHODS: For this prospective observational study, we recruited patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Monin, Leticia, Laing, Adam G, Muñoz-Ruiz, Miguel, McKenzie, Duncan R, del Molino del Barrio, Irene, Alaguthurai, Thanussuyah, Domingo-Vila, Clara, Hayday, Thomas S, Graham, Carl, Seow, Jeffrey, Abdul-Jawad, Sultan, Kamdar, Shraddha, Harvey-Jones, Elizabeth, Graham, Rosalind, Cooper, Jack, Khan, Muhammad, Vidler, Jennifer, Kakkassery, Helen, Sinha, Shubhankar, Davis, Richard, Dupont, Liane, Francos Quijorna, Isaac, O'Brien-Gore, Charlotte, Lee, Puay Ling, Eum, Josephine, Conde Poole, Maria, Joseph, Magdalene, Davies, Daniel, Wu, Yin, Swampillai, Angela, North, Bernard V, Montes, Ana, Harries, Mark, Rigg, Anne, Spicer, James, Malim, Michael H, Fields, Paul, Patten, Piers, Di Rosa, Francesca, Papa, Sophie, Tree, Timothy, Doores, Katie J, Hayday, Adrian C, Irshad, Sheeba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078907/
https://www.ncbi.nlm.nih.gov/pubmed/33930323
http://dx.doi.org/10.1016/S1470-2045(21)00213-8

Ejemplares similares

Ejemplares similares